Operations and Business Environment - Fresenius Medical Care

The Management’s General Assessment of
Business Performance
In the opinion of the Management Board, Fresenius
Medical Care developed in an exceptionally positive way
in 2006. The Company’s revenue and earnings climbed
to record levels. We achieved or exceeded all of the
main goals we had set ourselves at the beginning of
2006. All regions and business areas contributed to
this development.
Our company grew more strongly than the dialysis
market as a whole and further expanded its share of
the market. With the acquisition of Renal Care Group,
we bolstered our position in the segment with the
highest revenue, the North American region. Our
business outside North America, in the “International”
segment, also grew significantly more strongly than
the market.
Fresenius Medical Care significantly increased its operating
margin (EBIT margin) in North America and
“International”. We also significantly increased the
net income. These are clear indicators that we were
able to further strengthen our profitability.
67
With the acquisition of Nabi Biopharmaceuticals’ phosphate
binder business in North America, we expanded
our therapy offer for patients with chronic kidney
failure and thus have made the next step towards becoming
a provider of integrated therapies. As such, we
can further improve the quality of treatment and take
advantage of new growth opportunities worldwide.
Fresenius Medical Care 2006